S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
Log in
NASDAQ:GTHX

G1 Therapeutics Stock Forecast, Price & News

$21.40
+0.41 (+1.95 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$20.35
Now: $21.40
$21.54
50-Day Range
$17.58
MA: $19.18
$21.69
52-Week Range
$8.80
Now: $21.40
$25.79
Volume1.00 million shs
Average Volume1.13 million shs
Market Capitalization$814.18 million
P/E RatioN/A
Dividend YieldN/A
Beta2.44
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
G1 Therapeutics logo

MarketRank

Overall MarketRank

1.51 out of 5 stars

Medical Sector

405th out of 1,926 stocks

Pharmaceutical Preparations Industry

207th out of 773 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GTHX
CUSIPN/A
Phone919-213-9835
Employees104

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.80 per share

Profitability

Net Income$-122,450,000.00

Miscellaneous

Market Cap$814.18 million
Next Earnings Date2/24/2021 (Estimated)
OptionableOptionable
$21.40
+0.41 (+1.95 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GTHX News and Ratings via Email

Sign-up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions

How has G1 Therapeutics' stock been impacted by Coronavirus (COVID-19)?

G1 Therapeutics' stock was trading at $14.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GTHX shares have increased by 47.7% and is now trading at $21.40.
View which stocks have been most impacted by COVID-19
.

Is G1 Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" G1 Therapeutics stock.
View analyst ratings for G1 Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than G1 Therapeutics?

Wall Street analysts have given G1 Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but G1 Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as G1 Therapeutics' CEO?

1,448 employees have rated G1 Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among G1 Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is G1 Therapeutics' next earnings date?

G1 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for G1 Therapeutics
.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) released its quarterly earnings data on Wednesday, November, 4th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.06. The firm earned $26.60 million during the quarter, compared to the consensus estimate of $40 million.
View G1 Therapeutics' earnings history
.

What price target have analysts set for GTHX?

7 analysts have issued 12 month price objectives for G1 Therapeutics' stock. Their forecasts range from $21.00 to $82.00. On average, they anticipate G1 Therapeutics' share price to reach $50.17 in the next twelve months. This suggests a possible upside of 134.4% from the stock's current price.
View analysts' price targets for G1 Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of G1 Therapeutics' key competitors?

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

Who are G1 Therapeutics' key executives?

G1 Therapeutics' management team includes the following people:
  • Ms. Jennifer K. Moses, Chief Financial Officer (Age 46, Pay $441.6k)
  • Dr. Mark A. Velleca, Sr. Advisor & Director (Age 57, Pay $878.21k)
  • Dr. Rajesh K. Malik, Chief Medical Officer and Sr. VP of R&D (Age 62, Pay $560.17k)
  • Mr. Mark Avagliano, Chief Bus. Officer (Age 45, Pay $559.74k)
  • Mr. John E. Bailey Jr., CEO, Pres & Director (Age 56)
  • Mr. Terry L. Murdock, Chief Operating Officer (Age 61)
  • Mr. Alexander D. Smith M.S., VP of Technical Operations
  • Dr. Jay C. Strum, Chief Scientific Officer (Age 57)
  • Mr. Jeff Macdonald, Sr. Director of Investor Relations & Corp. Communications
  • Mr. Blake Jensen, VP of Quality & Compliance

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.63%) and Pacer Advisors Inc. (0.01%). Company insiders that own G1 Therapeutics stock include Glenn P Muir, James S Hanson, Mark A Velleca, Rajesh Malik and Seth Rudnick.
View institutional ownership trends for G1 Therapeutics
.

Which institutional investors are buying G1 Therapeutics stock?

GTHX stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, and Pacer Advisors Inc.. Company insiders that have bought G1 Therapeutics stock in the last two years include Glenn P Muir, and James S Hanson.
View insider buying and selling activity for G1 Therapeutics
or or view top insider-buying stocks.

How do I buy shares of G1 Therapeutics?

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $21.40.

How big of a company is G1 Therapeutics?

G1 Therapeutics has a market capitalization of $814.18 million. The company earns $-122,450,000.00 in net income (profit) each year or ($3.27) on an earnings per share basis. G1 Therapeutics employs 104 workers across the globe.

What is G1 Therapeutics' official website?

The official website for G1 Therapeutics is www.g1therapeutics.com.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.